Description: SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
Home Page: www.synactpharma.com
Scheelevägen 2
Lund,
223 81
Sweden
Phone:
46 28 44 75 67
Officers
| Name | Title |
|---|---|
| Mr. Jeppe Ovli Ovlesen EE, MBA | CEO, MD & Pres |
| Dr. Thomas Jonassen M.D. | Chief Scientific Officer & Director |
| Mr. Patrik Renblad | Chief Financial Officer |
| Dr. Thomas Boesen Ph.D. | Chief Operating Officer |
| Mr. Henrik Stage M.Sc. | Special Advisor to the CEO |
| Mr. James Knight | Chief Bus. Officer |
| Dr. Anders Dyhr Toft M.D., Ph.D. | Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 26.5718 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |